<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="28288">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01733316</url>
  </required_header>
  <id_info>
    <org_study_id>RP103-07</org_study_id>
    <secondary_id>2012-002773-64</secondary_id>
    <nct_id>NCT01733316</nct_id>
  </id_info>
  <brief_title>Open-Label Safety &amp; Superior Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Cystinosis</brief_title>
  <official_title>A Long-Term, Open-Label, Safety and Superior Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Patients With Cystinosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Raptor Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Raptor Pharmaceuticals Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to gather information about the effectiveness (how well it
      works to treat cystinosis) and safety of a new form of cysteamine bitartrate called RP103,
      compared to the already-approved drug cystinosis patients are taking called Cystagon®.

      In cystinosis, the body builds up cystine.  When taken regularly, the active ingredient of
      Cystagon® (cysteamine bitartrate) reduces cystine in the body.  RP103 has the same active
      ingredient as Cystagon® and is designed to reduce cystine in a similar way that Cystagon®
      does.  To decide if RP103 is better than Cystagon®, the study will look at two types of
      blood tests.  One test is pharmacodynamics (PD), which measures the amount of white blood
      cell (WBC) cystine after taking study drug.  WBC cystine is a laboratory test used to find
      out if cysteamine bitartrate is reducing cystine levels in the body.  The second test is
      pharmacokinetics (PK), which measures the amount of cysteamine in the blood after taking the
      drug.

      RP103 is different from Cystagon®:  Instead of the cysteamine bitartrate being absorbed from
      the stomach, RP103 is designed to be absorbed from the small intestine.  This may make the
      effects of the drug last longer, so that it can be taken twice a day instead of four times a
      day like Cystagon®.

      Some cystinosis patients have bad breath (halitosis) when they take Cystagon®.  Study
      participants who experience bad breath with Cystagon® will be asked if they would like to
      participate in an optional &quot;halitosis substudy&quot; to investigate this issue by collecting some
      extra PK blood samples.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>White Blood Cell (WBC) Cystine Levels</measure>
    <time_frame>7 Months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Superior effectiveness of RP103 vs. Cystagon® will be evaluated comparing WBC cystine levels during two 3-month treatment periods (Cystagon® and RP103). An interim analysis will be performed after 20 subjects complete the two treatment periods; A final analysis will be performed after all 60 subjects have completed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Long-Term Safety and Tolerability</measure>
    <time_frame>7 Months minimum; 24 months maximum</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The safety profile of RP103 will be investigated with the following assessments:  physical examination, vital signs, ECG, clinical laboratory testing and adverse events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life - General</measure>
    <time_frame>7 months minimum; 24 months maximum</time_frame>
    <safety_issue>No</safety_issue>
    <description>Long-term general quality of life will be assessed using instruments appropriate to the subjects' age and region (US or Europe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life - Fatigue/Sleep</measure>
    <time_frame>7 months; 24 months maximum</time_frame>
    <safety_issue>No</safety_issue>
    <description>Long-term quality of life, specifically fatigue/sleep, will be assessed using instruments appropriate to the subjects' age and region (US or Europe).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Cystinosis</condition>
  <arm_group>
    <arm_group_label>Cystagon Q6H</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>From Screening and during Months 1, 2, 3: all subjects will take Cystagon (cysteamine bitartrate) every 6 hours, supplied in 150 and 50mg capsules.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RP103 Q12H</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>From Months 3.5, 4, 5, 6, 7 and the remainder of participation: all subjects will take RP103 (cysteamine bitartrate delayed-release capsules) every 12 hours, supplied in 75 and 25mg capsules.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RP103 Q12H</intervention_name>
    <arm_group_label>RP103 Q12H</arm_group_label>
    <other_name>RP103 (cysteamine bitartrate delayed-release capsules)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cystagon Q6H</intervention_name>
    <arm_group_label>Cystagon Q6H</arm_group_label>
    <other_name>Cystagon (cysteamine bitartrate)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

          -  Male or female with a documented diagnosis of cystinosis

          -  On a stable dose of Cystagon at least 21 days prior to Screening

          -  WBC cystine level &gt; 1 nmol 1/2 cystine/mg of protein, on average over at least 2
             measurements collected during the 2 years prior to Screening

          -  No clinically significant change in liver function tests, i.e. 1.5 times ULN for ALT
             and AST, and/or 1.5 times ULN for total bilirubin, within 6 months prior to Screening

          -  No clinically significant change in renal function, i.e. estimated GFR within 6
             months prior to Screening

          -  Must have an estimated GFR &gt; 20 mL/minute/1.73m2 (using the equation from Schwartz
             2009 J Am Soc Nephrol 20:629-647)

          -  Female subjects who are sexually active and of childbearing potential, i.e. not
             surgically sterile (tubal ligation, bilateral oophorectomy, or hysterectomy) or at
             least 2 years naturally postmenopausal must agree to use an acceptable form of
             contraception from Screening through completion of the study.  Acceptable forms of
             contraception for this study include hormonal contraceptives (oral, implant,
             transdermal patch, or injection) at a stable dose for at least 3 months prior to
             Screening, barrier (spermicidal condom or diaphragm with spermicide), IUD, or a
             partner who has been vasectomized for at least 6 months.

          -  Subject or their parent or guardian must provide written informed consent, assent
             (where applicable), prior to participation in the study

        EXCLUSION CRITERIA:

          -  Younger than 12 years of age

          -  Current history of the following conditions or any other health issues that make it,
             in the opinion of the investigator, unsafe for study participation:

               -  Inflammatory bowel disease if currently active, or prior resection of the small
                  intestine;

               -  Heart disease (e.g., myocardial infarction, heart failure, unstable arrhythmias,
                  or poorly controlled hypertension) within 90 days prior to Screening;

               -  Active bleeding disorder within 90 days prior to Screening;

               -  History of malignant disease within 2 years prior to Screening

          -  Hemoglobin level of &lt; 9 g/dL at Screening or, in the opinion of the investigator, a
             hemoglobin level that would make it unsafe for study participation

          -  Known hypersensitivity to cysteamine and penicillamine

          -  Female subjects who are nursing, planning a pregnancy, or are known or suspected to
             be pregnant

          -  Subjects who, in the opinion of the investigator, are not able or willing to comply
             with study requirements
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurence A Greenbaum, MD, PhD (US)</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Georges Deschênes, MD, PhD (EU)</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Robert Debré</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mary Jo Bagger, Clinical Operations, Raptor Pharmaceuticals Inc.</last_name>
    <phone>1-415-408-6210</phone>
    <email>mbagger@raptorpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>California Pacific Medical Center (CPMC) Research Institute</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical School</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Emory Children's Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine / Texas Childrens Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University Hospital of Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Levtchenko, MD, PhD</last_name>
      <phone>+32 16 343827</phone>
      <email>elena.levtchenko@uz.kuleuven.ac.be</email>
    </contact>
    <contact_backup>
      <last_name>Maria van Dyck, MD</last_name>
      <phone>+32 (16) 343827</phone>
      <email>maria.vandyck@uzleuven.be</email>
    </contact_backup>
    <investigator>
      <last_name>Elena Levtchenko, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurelia Bertholet-Thomas, MD</last_name>
      <phone>+33 (4) 72 11 03 51</phone>
      <email>aurelia.bertholet-thomas@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Segolene Gaillard</last_name>
      <phone>+33 (4) 72 35 75 51</phone>
      <email>segolene.gaillard@chu-lyon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Pierre Cochat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker-Enfants Malades</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agnés Mogenet, MD</last_name>
      <phone>+33 (1) 44 49 47 44</phone>
      <email>agnes.mogenet@nck.ap-hop-paris.fr</email>
    </contact>
    <contact_backup>
      <last_name>, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Rémi Salomon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Robert Debré</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florence Emmanuel</last_name>
      <phone>+33 (1) 40 03 36 41</phone>
      <email>florence.emmanuel@rdb.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Georges Deschênes, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Pediatrico Bambino Gesù</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcella Greco, MD</last_name>
      <email>marcella.greco@opbg.net</email>
    </contact>
    <contact_backup>
      <last_name>Susanna Livadiotti</last_name>
      <phone>+39 (06) 68 59 30 81</phone>
      <email>susanna.livadiotti@opbg.net</email>
    </contact_backup>
    <investigator>
      <last_name>Marcella Greco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radboud University Nijmegen Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariette Las</last_name>
      <phone>+31 (24) 36 68 957</phone>
      <email>mariette.las@radboudumc.nl</email>
    </contact>
    <investigator>
      <last_name>Marlies Cornelissen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital Birmingham</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Graham Lipkin, MD, FRCP</last_name>
      <email>graham.lipkin@uhb.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Farfia Capper</last_name>
      <phone>+44 (0) 12 13 73 31 70</phone>
      <email>farfia.capper@uhb.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Graham Lipkin, MD, FRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William van't Hoff, MD, FRCPCH</last_name>
      <email>vanthw@gosh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>William van't Hoff, MD, FRCPCH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guy's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marlies Ostermann, MD, PhD</last_name>
      <email>marlies.ostermann@gstt.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>James Dobbyn</last_name>
      <phone>020 71887188</phone>
      <phone_ext>43926</phone_ext>
      <email>james.dobbyn@gstt.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Marlies Ostermann, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://procysbi.com/</url>
    <description>RP103 (marketed as PROCYSBI) is now approved by the US FDA for management of nephropathic cystinosis in patients 6 years and older.</description>
  </link>
  <reference>
    <citation>Schwartz GJ, Muñoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009 Mar;20(3):629-37. Epub 2009 Jan 21.</citation>
    <PMID>19158356</PMID>
  </reference>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 8, 2014</lastchanged_date>
  <firstreceived_date>November 16, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nephropathic Cystinosis</keyword>
  <keyword>Cysteamine</keyword>
  <keyword>Delayed-Release Cysteamine</keyword>
  <keyword>Orphan Disease</keyword>
  <keyword>CTNS Protein, Human</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cystinosis</mesh_term>
    <mesh_term>Nephrotic Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cysteamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
